NovoCure's FDA Setback: Time to Sell NVCR?

NovoCure (NVCR) announced that the FDA issued a not approvable letter for its investigational device, Optune Mya, intended to treat non-small cell lung cancer that has metastasized to the brain. The FDA cited uncertainty around the clinical benefit of the device, though it raised no safety concerns.

The company had submitted a premarket approval (PMA) application for Optune Mya, which uses tumor treating fields (TTFields) technology to disrupt cancer cell division. The device is part of NovoCure's Optune family, which includes the Gio for glioblastoma, the Lua for thoracic cancers, and the Pax for pancreatic cancer.

NovoCure stated it is evaluating the FDA's response and plans to meet with the agency to discuss a potential path to approval without additional clinical trials. The news sent shares down as much as 10% intraday, though they recovered to close 7.34% lower.

The rejection comes at a challenging time for NovoCure, which remains unprofitable despite revenue growth. In the third quarter, the company reported a net loss of $10.4 million, narrower than the prior year's loss, but still a loss. The Gio remains the primary revenue driver with 4,729 active patients, while Lua and Pax are still in earlier stages of adoption.

The FDA's rejection of Optune Mya is a significant blow to NovoCure's growth pipeline. The device was seen as a potential new revenue stream in a large market—lung cancer with brain metastases—and its delay or denial limits the company's near-term expansion opportunities.

Without Mya, NovoCure must rely on its existing products, which face their own challenges. The Gio, while established, is a maturing product with slower growth. The Lua is growing but from a small base, and the Pax is just launching but faces competition from Revolution Medicines' Rasonque, a pill approved for stage 4 metastatic pancreatic cancer.

The FDA's decision also raises questions about the regulatory pathway for NovoCure's TTFields technology in new indications. The agency's focus on clinical benefit uncertainty suggests that future approvals may require more robust data, potentially increasing development costs and timelines.

Financially, NovoCure remains unprofitable, and the rejection could delay its path to profitability. While the company has raised its revenue and adjusted EBITDA guidance for 2026, the loss of a key pipeline asset may force analysts to reassess those projections. Investor sentiment is likely to remain negative until there is clarity on Mya's future or other catalysts emerge.